Trial Profile
Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Sep 2015
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriasis; Sleep apnoea syndrome
- Focus Therapeutic Use
- 26 Jul 2012 Primary endpoint 'Apnea-hypopnea-index' has not been met.
- 01 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Aug 2011 Planned end date changed from 1 Dec 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.